15255-86-4

Basic information

• Product Name: Carbamic acid, (phenylmethoxy)-, phenylmethyl ester
• CAS NO: 15255-86-4
• Molecular Formula: C15H15NO3
• Molecular Weight: 257.289
• Mol File: 15255-86-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Carbamic acid, (phenylmethoxy)-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (phenylmethoxy)-, phenylmethyl ester(15255-86-4)
• EPA Substance Registry System: Carbamic acid, (phenylmethoxy)-, phenylmethyl ester(15255-86-4)

Safety Data

• Hazardous Substances Data: 15255-86-4(Hazardous Substances Data)

Upstream product

• 501-53-1 benzyl chloroformate 
• 3426-71-9 Benzyl N-hydroxycarbamate 
• 100-39-0 benzyl bromide 
• 2687-43-6 O-benzylhydoxylamine hydrochloride 
• 622-33-3 N-benzyloxyamine 

Downstream Products

• 83948-57-6 C₂₃H₃₀N₂O₅ 
• 125049-88-9 tert-butyl ester of α-N-(allyloxycarbonyl)-δ-N-carbobenzoxy-δ-N-(benzyloxy)ornithine 
• 125049-90-3 tert-butyl ester of α-N-carbobenzoxy-δ-N-(allyloxycarbonyl)-δ-N-(benzyloxy)-D-ornithine 
• 94136-61-5 1-<(tert-butoxycarbonyl)amino>-5-<(benzyloxycarbonyl)(benzyloxy)amino>pentane 
• 90219-04-8 L-N⁽²⁾-Boc-N⁽⁵⁾-Cbz-N⁽⁵⁾-benzyloxyornithine tert-butyl ester 
• 607714-32-9 C₃₁H₄₅N₃O₅ 
• 110272-02-1 N-carbobenzoxy-N-methyl-O-benzylhydroxylamine 
• 1454273-75-6 N-(benzyloxyl)-(4-bromo-butanoyl)-carbamic acid benzyl ester 
• 1367359-54-3 ethyl 3-[(benzyloxy)-(benzyloxycarbonyl)amino]-4,4,4-trifluorobutanoate 
• 1179974-38-9 Boc-Dab(N-Cbz-N'-benzyloxy)-OAll 
• 1179974-47-0 Boc-γ-Glu[-Dab(N-Cbz-N'-benzyloxy)-OAll]-OtBu 

Relevant articles and documents

GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

Alkyl 4-chlorobenzoyloxycarbamates as highly effective nitrogen source reagents for the base-free, intermolecular aminohydroxylation reaction

Ethyl-(7), benzyl-(8), tert-butyl-(9), and fluorenylmethyl-4- chlorobenzoyloxycarbamates (10) have been prepared as storable and easy-to-prepare nitrogen sources for use in the intermolecular Sharpless aminohydroxylation reaction and its asymmetric variant. These reagents were found to be effective under base-free reaction conditions. The scope and limitations of these methods have been explored using a variety of alkenes, among which, trans-cinnamates, in particular, proved to be good substrates.

Novel matrix metalloproteinase inhibitors: Generation of lead compounds by the in silico fragment-based approach

Generation of structurally new matrix metalloproteinase inhibitors was successfully carried out using an in silico technique. In order to identify the small fragment interacting with residues in the S1′ pocket of MMP-1 through hydrogen bonds, we performed in silico screening using the LUDI program. As a result, acetyl-l-alanyl-(N-methyl)amide (Ac-l-Ala-NHMe) was selected to link with another fragment, hydroxamic acid that interacted with catalytic zinc. By this approach, the l-glutamic acid derivative 2b was discovered to be a new type of matrix metalloproteinase inhibitor. Further transformation to reduce its peptidic nature and improve activity yielded nonpeptidic lead compounds as inhibitors of MMP-1, -2, -3, and -9.